"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead
Original article
peer-reviewed

Valuation of Neutrophil/Lymphocyte Ratio in Renal Cell Carcinoma Grading and Progression



Abstract

Introduction

We investigated the association of the neutrophil/lymphocyte ratio (NLR) with tumor size and Fuhrman grade in nonmetastatic renal cell carcinoma (RCC) cases.

Materials and methods

Data of nonmetastatic RCC (T1-4N0M0) cases, operated between 2010 and 2016, were retrospectively reviewed and 103 patients were included in the study. The patients were divided into two groups according to tumor diameter (Group 1 T < 4 cm, Group 2 T ≥ 4 cm) and into three groups according to Fuhrman grade. Twenty-eight patients with a tumor diameter of 4 cm or less in Group 1 and 75 patients with a tumor diameter greater than 4 cm in Group 2 were compared. In both grouping systems, the NLR, mean platelet volume (MPV), red cell distribution width (RDW), white blood cell (WBC), red blood cell (RBC), platelet (PLT), lymphocyte, and neutrophil values and age were compared.

Results

There were no differences in age, MPV, RDW, neutrophil, WBC, RBC, PLT counts in groups of tumor diameter (Group 1 T < 4 cm, Group 2 T ≥ 4 cm). However, the lymphocyte amount was significantly higher in cases with a tumor diameter less than 4 cm compared to the cases with a tumor diameter greater than 4 cm (p = 0.015). It was observed that the NLR had a tendency to increase in patients with tumor size greater than 4 cm compared to patients with tumor size smaller than 4 cm (p = 0.029). There were no differences in age, MPV, RDW, lymphocyte, neutrophil, WBC, RBC, PLT counts, and the NLR in different Fuhrman-graded cases.

Conclusions

There is a linear relation between the tumor size and the NLR in nonmetastatic RCC cases. Therefore, the NLR is a cheap parameter that can be used to show the tumor size, and thus it can be used to get an idea about the prognosis of the patient.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Original article
peer-reviewed

Valuation of Neutrophil/Lymphocyte Ratio in Renal Cell Carcinoma Grading and Progression


Author Information

Ersan Arda

Urology, Trakya University Medical Faculty

Ilkan Yuksel Corresponding Author

Urology, Private Bir Nefes Hospital

Urology, Trakya University Medical Faculty

Basri Cakiroglu

Urology, Hisar Intercontinental Hospital

Esra Akdeniz

Biostatistics, Marmara University School of Medicine

Bioistatistics, Marmara University School of Medicine

Nusret Cilesiz

Urology, Taksim Eah


Ethics Statement and Conflict of Interest Disclosures

Human subjects: Consent was obtained by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.


Original article
peer-reviewed

Valuation of Neutrophil/Lymphocyte Ratio in Renal Cell Carcinoma Grading and Progression


Figures etc.

Share
Original article
peer-reviewed

Valuation of Neutrophil/Lymphocyte Ratio in Renal Cell Carcinoma Grading and Progression

  • Author Information
    Ersan Arda

    Urology, Trakya University Medical Faculty

    Ilkan Yuksel Corresponding Author

    Urology, Private Bir Nefes Hospital

    Urology, Trakya University Medical Faculty

    Basri Cakiroglu

    Urology, Hisar Intercontinental Hospital

    Esra Akdeniz

    Biostatistics, Marmara University School of Medicine

    Bioistatistics, Marmara University School of Medicine

    Nusret Cilesiz

    Urology, Taksim Eah


    Ethics Statement and Conflict of Interest Disclosures

    Human subjects: Consent was obtained by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

    Acknowledgements


    Article Information

    Published: January 10, 2018

    DOI

    10.7759/cureus.2051

    Cite this article as:

    Arda E, Yuksel I, Cakiroglu B, et al. (January 10, 2018) Valuation of Neutrophil/Lymphocyte Ratio in Renal Cell Carcinoma Grading and Progression. Cureus 10(1): e2051. doi:10.7759/cureus.2051

    Publication history

    Received by Cureus: November 17, 2017
    Peer review began: November 27, 2017
    Peer review concluded: January 06, 2018
    Published: January 10, 2018

    Copyright

    © Copyright 2018
    Arda et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    License

    This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Introduction

We investigated the association of the neutrophil/lymphocyte ratio (NLR) with tumor size and Fuhrman grade in nonmetastatic renal cell carcinoma (RCC) cases.

Materials and methods

Data of nonmetastatic RCC (T1-4N0M0) cases, operated between 2010 and 2016, were retrospectively reviewed and 103 patients were included in the study. The patients were divided into two groups according to tumor diameter (Group 1 T < 4 cm, Group 2 T ≥ 4 cm) and into three groups according to Fuhrman grade. Twenty-eight patients with a tumor diameter of 4 cm or less in Group 1 and 75 patients with a tumor diameter greater than 4 cm in Group 2 were compared. In both grouping systems, the NLR, mean platelet volume (MPV), red cell distribution width (RDW), white blood cell (WBC), red blood cell (RBC), platelet (PLT), lymphocyte, and neutrophil values and age were compared.

Results

There were no differences in age, MPV, RDW, neutrophil, WBC, RBC, PLT counts in groups of tumor diameter (Group 1 T < 4 cm, Group 2 T ≥ 4 cm). However, the lymphocyte amount was significantly higher in cases with a tumor diameter less than 4 cm compared to the cases with a tumor diameter greater than 4 cm (p = 0.015). It was observed that the NLR had a tendency to increase in patients with tumor size greater than 4 cm compared to patients with tumor size smaller than 4 cm (p = 0.029). There were no differences in age, MPV, RDW, lymphocyte, neutrophil, WBC, RBC, PLT counts, and the NLR in different Fuhrman-graded cases.

Conclusions

There is a linear relation between the tumor size and the NLR in nonmetastatic RCC cases. Therefore, the NLR is a cheap parameter that can be used to show the tumor size, and thus it can be used to get an idea about the prognosis of the patient.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Ersan Arda, M.D., Assistant Professor

Urology, Trakya University Medical Faculty

Ilkan Yuksel

Urology, Private Bir Nefes Hospital

For correspondence:
ilkanyuksel@hotmail.com

Basri Cakiroglu

Urology, Hisar Intercontinental Hospital

Esra Akdeniz

Biostatistics, Marmara University School of Medicine

Nusret Cilesiz

Urology, Taksim Eah

Ersan Arda, M.D., Assistant Professor

Urology, Trakya University Medical Faculty

Ilkan Yuksel

Urology, Private Bir Nefes Hospital

For correspondence:
ilkanyuksel@hotmail.com

Basri Cakiroglu

Urology, Hisar Intercontinental Hospital

Esra Akdeniz

Biostatistics, Marmara University School of Medicine

Nusret Cilesiz

Urology, Taksim Eah